Spire Wealth Management Sells 653 Shares of The Clorox Company $CLX

Spire Wealth Management trimmed its holdings in shares of The Clorox Company (NYSE:CLX) by 74.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 220 shares of the company’s stock after selling 653 shares during the period. Spire Wealth Management’s holdings in Clorox were worth $26,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of CLX. American National Bank & Trust boosted its holdings in Clorox by 69.5% during the 2nd quarter. American National Bank & Trust now owns 217 shares of the company’s stock valued at $26,000 after acquiring an additional 89 shares during the period. Ransom Advisory Ltd bought a new stake in Clorox in the first quarter valued at approximately $35,000. Hantz Financial Services Inc. purchased a new stake in shares of Clorox during the second quarter valued at approximately $31,000. GW&K Investment Management LLC grew its holdings in shares of Clorox by 239.1% in the first quarter. GW&K Investment Management LLC now owns 295 shares of the company’s stock worth $43,000 after purchasing an additional 208 shares during the last quarter. Finally, Roble Belko & Company Inc increased its stake in shares of Clorox by 140.7% in the first quarter. Roble Belko & Company Inc now owns 361 shares of the company’s stock worth $53,000 after buying an additional 211 shares during the period. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Trading Up 1.0%

NYSE CLX opened at $107.37 on Friday. The firm has a market capitalization of $13.07 billion, a PE ratio of 16.47, a P/E/G ratio of 0.92 and a beta of 0.52. The stock’s 50 day moving average is $119.49 and its 200 day moving average is $124.94. The Clorox Company has a twelve month low of $106.14 and a twelve month high of $171.37. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.78 by $0.07. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The business had revenue of $1.43 billion during the quarter, compared to analyst estimates of $1.41 billion. During the same quarter last year, the firm posted $1.86 earnings per share. The company’s revenue for the quarter was down 18.9% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. Research analysts forecast that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Wednesday, October 22nd. This represents a $4.96 annualized dividend and a yield of 4.6%. Clorox’s payout ratio is presently 77.86%.

Insiders Place Their Bets

In related news, COO Eric H. Reynolds sold 15,041 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total value of $1,861,774.98. Following the sale, the chief operating officer owned 54,221 shares in the company, valued at $6,711,475.38. This represents a 21.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.63% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Clorox in a research report on Tuesday, October 14th. Zacks Research cut Clorox from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 28th. JPMorgan Chase & Co. reduced their price target on Clorox from $127.00 to $120.00 and set a “neutral” rating on the stock in a report on Tuesday. Citigroup dropped their price objective on Clorox from $130.00 to $120.00 and set a “neutral” rating for the company in a report on Tuesday. Finally, Barclays reduced their target price on Clorox from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Tuesday, September 30th. One research analyst has rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $127.60.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.